PNC-27: Research Overview
Experimental anticancer peptide studied in cell and animal models. No human trials have been run.
Also known as PNC27
What is PNC-27?
PNC-27 is an experimental anti-cancer peptide created by a supercomputer at SUNY Downstate Medical Center in 2000. It contains an HDM-2 binding domain from p53 (residues 12-26) linked to a cell-penetrating domain. The peptide selectively kills cancer cells by binding to HDM-2 (MDM2) expressed on cancer cell membranes, forming pores that cause cell necrosis.
What is PNC-27 researched for?
- PNC-27 shows selective cytotoxicity against pancreatic cancer cells in research.
- Demonstrated effectiveness against breast cancer cell lines.
- Induces necrosis of K-562 leukemia cells through HDM-2 binding.
- Shows selective targeting of melanoma cells.
- Most effective against cancers with high membrane HDM-2 expression.
- Model compound for studying cancer-selective therapies.
How does PNC-27 work?
PNC-27 exploits a unique vulnerability of cancer cells: the presence of HDM-2 (human double minute 2, also called MDM2) on their cell surface. The peptide's p53 residues adopt a conformation that binds directly to membrane-bound HDM-2, inducing transmembrane pore formation. This causes rapid tumor cell necrosis (not apoptosis).
References
Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes PNAS
2010
PNC-27 binds membrane-bound HDM-2, inducing pore formation and cancer cell necrosis while sparing normal cells.
Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes PubMed
2024
PNC-27 also enters cancer cells and disrupts mitochondrial membranes.
PNC-27 Induces Tumor Cell Necrosis of Leukemia Cells Annals of Clinical & Laboratory Science
2014
PNC-27 induces necrosis of K-562 leukemia cells lacking p53 through p53-independent pathway.
PNC-27, a Chimeric p53-Penetratin Peptide PubMed
2022
PNC-27 binds HDM-2 in p53 peptide-like structure, induces selective membrane-pore formation leading to cancer cell lysis.
This information is for educational and research purposes only. Consult a healthcare professional before use.
A comprehensive research database for peptides, therapies, and protocols. Information provided for educational purposes only.
© 2026 Peptide Database. For educational and research purposes only.
Common questions
Why is PNC-27 described as 'cancer cell-selective' when normal cells can express HDM-2?
The key difference is location. Normal cells express HDM-2 intracellularly, not on their cell surface. PNC-27 requires membrane-bound HDM-2 to form pores. Cancer cells uniquely express HDM-2 on their plasma membrane, making them susceptible to attack while normal cells are completely spared. This surface expression is a cancer-specific vulnerability.
Is PNC-27 closer to clinical trials than other peptide cancer therapies?
Not yet. PNC-27 remains in preclinical research with no human clinical trials initiated as of 2025. While it's been studied since 2000, it hasn't progressed to human testing. That's partly because cancer drug development is slow and partly because peptide therapeutics face delivery challenges that are being actively researched.
Could PNC-27 work on cancers that don't express HDM-2?
No. PNC-27's entire mechanism depends on membrane HDM-2 binding. Cancers without membrane HDM-2 expression wouldn't respond. This is both a strength (high selectivity) and a limitation (requires the right cancer type). Assessing HDM-2 status would be critical before attempting any therapeutic use.